drugset / Trial / NCT07301138
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
NaSingle-groupOpen-labelTreatment
Summary
This investigator-initiated, prospective, single-arm, multicenter clinical trial aims to evaluate the efficacy and safety of BEBT-908 (a HDAC/PI3Kα inhibitor provided by BeBetter Med Inc ,Guangzhou, China) combined with chemotherapy in patients with MEF2D-rearranged and pre-B acute lymphoblastic leukemia who are in complete remission (CR) but remain minimal residual disease (MRD) positive.
Timeline
- Start
- 2025-12-15
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BEBT-908 | Unknown | 12.3 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 150 mg/m2 | — |
| Background | Cytarabine | Small molecule | 0.5 g | — |
| Background | Dexamethasone | Small molecule | 20 mg | — |
| Background | Methotrexate | Small molecule | 1 g | — |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | — |